Risk Management Assessments Will Be Part Of Advisory Committees - FDA
Executive Summary
Risk management and other postmarketing safety considerations should be discussed during pre-approval advisory committee meetings, CDER participants maintained in a June 22 satellite workshop on minimizing pharmaceutical contributions to medical errors.
You may also be interested in...
Off Label Drug Use Data To Be Required In Periodic Safety Updates - FDA
Pharmaceutical companies will be asked to provide postmarketing drug usage information in their periodic safety update reports, including use in off label indications, under a proposed FDA rule due out later this year.
Off Label Drug Use Data To Be Required In Periodic Safety Updates - FDA
Pharmaceutical companies will be asked to provide postmarketing drug usage information in their periodic safety update reports, including use in off label indications, under a proposed FDA rule due out later this year.
FDA Adverse Event Draft Guidance Would Restrict "Well Tolerated" Claims
FDA would restrict the use of nonspecific safety claims such as "well tolerated" under its draft guidance on adverse event labeling.